Background Image
Previous Page  142 / 156 Next Page
Information
Show Menu
Previous Page 142 / 156 Next Page
Page Background

140

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

204

Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz

S,Fleischer W, Reimer K. A randomised controlled trial with prolonged-release oral oxyco-

done and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;

13(1): 56-64.

205

Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat

Rev 2006; 32(4): 304-315.

206

Mercadante S, Ferrera P, Arcuri E. The use of fentanyl buccal tablets as breakthrough

medication in patients receiving chronic methadone therapy: an open label preliminary

study. Support Care Cancer 2011; 19(3): 435-438.

207

Mercadante S, Intravaia G, Villari P, Ferrera P, David F, Casuccio A. Controlled sedation for

refractory symptoms in dying patients. J Pain Symptom Manage 2009; 37(5): 771-779.

208

Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S. Intrathecal

treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J

Pain 2007; 23(9): 793-798.

209

Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S. Intravenous morphine

for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J

Pain Symptom Manage 2008; 35(3): 307-313.

210

Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C. Low doses of transdermal

fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin 2010; 26(12):

2765-2768.

211

Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A. Low

doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week,

nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31(10):

2134-2138.

212

Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Ficorella C, Verna L, Tirelli W, Villari P,

Arcuri E. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom

Manage 2006; 31(3): 242-247.

213

Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia

V, Riina S, Casuccio A, Mangione S. Sustained-release oral morphine versus transdermal

fentanyl and oral methadone in cancer pain management. Eur J Pain 2008; 12(8): 1040-

1046.

214

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the

treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr

Med Res Opin 2009; 25(11): 2805-2815.

215

Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, Gebbia V. Morphine

versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain

2010; 26(9): 794-797.

216

Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal

fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for

episodic-breakthrough pain. Br J Cancer 2007; 96(12): 1828-1833.

Literaturverzeichnis